Brief: OSE Immunotherapeutics: Additional Financing For Its COVID Vaccine Candidate

Ose Immunotherapeutics SA

18/05/2021 06:43

May 18 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS ANNOUNCES €10.7 MILLION IN
ADDITIONAL
PUBLIC FUNDING, VIA BPIFRANCE, TO FINANCE FURTHER DEVELOPMENT OF
COVEPIT, ITS MULTI-TARGET AND MULTI-VARIANT COVID-19 VACCINE IN
PHASE 1 CLINICAL PHASE
    * COVEPIT IS A SARS-COV-2 VACCINE ACTIVATING T CELL DEFENCES
THROUGH CD8 T CELL MULTI-EPITOPES.
    * COVEPIT EPITOPES* ARE SELECTED FROM 11 VIRAL PROTEIN
TARGETS
DESIGNED TO COVER ALL INITIAL AND NEW EMERGING SARS-COV-2
VARIANTS
    * COVEPIT, A SECOND-GENERATION VACCINE, POTENTIALLY PROVIDES
A
LONG-TERM CELLULAR IMMUNITY WITH MEMORY T CELLS

Source text for Eikon:  ID:nBw5mXmG3a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))